about
Safety of targeting tumor endothelial cell antigensEnhancing the treatment effect on melanoma by heat shock protein 70-peptide complexes purified from human melanoma cell lines.Whole cell vaccination using immunogenic cell death by an oncolytic adenovirus is effective against a colorectal cancer model.In Vivo Expansion of Melanoma-Specific T Cells Using Microneedle Arrays Coated with Immune-Polyelectrolyte Multilayers.Advancing Cancer Therapy with Present and Emerging Immuno-Oncology ApproachesExosomes derived from tumor cells genetically modified to express Mycobacterium tuberculosis antigen: a novel vaccine for cancer therapy.Vaccine-based immunotherapeutic approaches to gliomas and beyond.Progress of dendritic cell-based cancer vaccines for patients with hematological malignancies.Progress in nonviral gene therapy for breast cancer and what comes next?Promising investigational drug candidates in phase I and phase II clinical trials for mesothelioma.The novel immunomodulator IMMUNEPOTENT CRP combined with chemotherapy agent increased the rate of immunogenic cell death and prevented melanoma growth.Polyelectrolyte-Enrobed Cancer Cells in View of Personalized Immune-TherapyDendritic cells based immunotherapy.A melanin-mediated cancer immunotherapy patch.STAT3-blocked whole-cell hepatoma vaccine induces cellular and humoral immune response against HCC.Informatics for cancer immunotherapy.Encapsulation of Hydrophilic and Hydrophobic Peptides into Hollow Mesoporous Silica Nanoparticles for Enhancement of Antitumor Immune Response.Exploiting lymphatic vessels for immunomodulation: Rationale, opportunities, and challenges.Nanocage-Therapeutics Prevailing Phagocytosis and Immunogenic Cell Death Awakens Immunity against Cancer.Cellular vaccination of MLH1-/- mice - an immunotherapeutic proof of concept study.Cancer Vaccines in Ovarian Cancer: How Can We Improve?High CD8+ and absence of Foxp3+ T lymphocytes infiltration in gallbladder tumors correlate with prolonged patients survival.Breast cancer vaccination comes to age: impacts of bioinformatics
P2860
Q26748863-F27C1598-ECA0-46A4-A682-D710ECEED874Q37142487-ED8C32EF-6528-4355-8468-58A9AF8F8102Q37502453-7A3349B6-5848-438E-BC24-28780BB5BCC1Q37682217-E3B7EF7D-BBF9-4CDD-A213-F264CD7FCE9FQ38689153-9F2E4FCE-C596-4430-B804-6D0133BBF19CQ38754223-894EA35B-2981-412B-B340-EC77C819D586Q38789860-1FFAA04E-1BF0-4384-B175-4746D81032AAQ38847756-284825DA-2FD4-45CD-9635-69BC313FCC5CQ39194052-C830FCA0-DB1B-4405-8B57-019DDC36601AQ39415827-C4BD5C7B-FA65-4547-BC2E-AA39FC3480FAQ40128947-AFD19525-5713-4B09-AB0A-B1733098A857Q42199258-37AB39F6-15A8-4AC9-A630-49971AAC8830Q43043935-435BDB74-C234-49E5-83CD-172C6BBEFE48Q44876957-00CA0285-C2D0-4064-A2A4-3E73F46FBC94Q47122059-28229830-E5EB-4CAD-A494-4DEBD6B60A4CQ47290509-A6982728-1773-435E-9F0C-5E37E3EC82E8Q47730028-51D301CC-C322-4255-9910-9CCF370DC77AQ47940254-C70EAA2F-7488-4071-B512-006A0071135DQ50048512-127F45E6-C2E2-4183-B70B-D0D1037D7727Q50423289-19447E8B-D185-4E22-B898-0D934F39ABB0Q54385315-5B085357-F511-4862-8480-74ACE9A836E7Q54934803-04B7193F-F8FD-4791-8104-ADE060E3B1A1Q57114951-3709A779-A323-47C0-86B8-7CBAFEFE4613
P2860
description
2015 nî lūn-bûn
@nan
2015 թուականին հրատարակուած գիտական յօդուած
@hyw
2015 թվականին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
name
Whole Tumor Antigen Vaccines: Where Are We?
@ast
Whole Tumor Antigen Vaccines: Where Are We?
@en
Whole Tumor Antigen Vaccines: Where Are We?
@nl
type
label
Whole Tumor Antigen Vaccines: Where Are We?
@ast
Whole Tumor Antigen Vaccines: Where Are We?
@en
Whole Tumor Antigen Vaccines: Where Are We?
@nl
prefLabel
Whole Tumor Antigen Vaccines: Where Are We?
@ast
Whole Tumor Antigen Vaccines: Where Are We?
@en
Whole Tumor Antigen Vaccines: Where Are We?
@nl
P2860
P3181
P356
P1433
P1476
Whole Tumor Antigen Vaccines: Where Are We?
@en
P2093
Cheryl Lai-Lai Chiang
Lana E Kandalaft
P2860
P304
P3181
P356
10.3390/VACCINES3020344
P407
P577
2015-04-23T00:00:00Z